Compare Ferrari NV (RACE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs GeneDx Holdings Corp — how do they compare? Ferrari NV trades at $409.61 (market cap $70.66B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Ferrari NV is far larger — about 27.4× GeneDx Holdings Corp's market cap, and Ferrari NV pays a 1.05% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| RACE | WGS | |
|---|---|---|
Market Cap | $70.66B | $2.58B |
Sector | Consumer Cyclical | Technology |
52-Week High | $504.09 | $167.51 |
52-Week Low | $314.63 | $34.51 |
Enterprise Value | $72.61B | $2.61B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $405.94, down 0.98% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $5.1B in 2022 to $7.1B in 2025, and robust profitability margins. Recent news highlights a record $40 million auction of its first electric car, reinforcing brand prestige. Analyst consensus is bullish with a $462.67 price target, though technical indicators suggest near-term pressure with support at $402 and resistance at $411.
The outlook remains positive due to Ferrari's pricing power and margin strength, but risks include high valuation multiples and economic sensitivity. Institutional buying and share repurchases provide support, yet investors face volatility from technical bearishness and competitive pressures in the luxury auto sector.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
